145 completed, 40 recruiting, 36 unknown, 35 active not recruiting. 314 Phase 2, 54 Phase 1, 33 Phase 3.
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE - Thyroid Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 18 | 2026-11-18 | 2026-11-13 |
| T4/T3 Therapy in Hypothyroidism Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo - Hypothyroidism Primary | Phase 2 | Not yet recruiting | University of Pennsylvania | 60 | 2026-11-01 | 2026-08-20 |
| Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) Sacituzumab Tirumotecan - Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic | Phase 2 | Not yet recruiting | National Cancer Centre, Singapore | 68 | 2026-11-01 | 2026-07-15 |
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease BHV-1300 - Graves' Disease | Phase 2 / Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 356 | 2026-10-01 | 2026-10-28 |
| MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment) - Thyroid Cancer, Tumor | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 | 2026-09-20 | 2026-10-14 |
| Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer Selective coverage radiotherapy, comprehensive coverage radiotherapy - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 72 | 2026-08-12 | 2026-08-20 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-08-01 | 2026-05-19 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-11-12 |
| Colchicine for Autoimmune and Subacute Thyroiditis colchicine, Prednisolone, NSAID - Hashimoto Thyroiditis, Subacute Thyroiditis | Phase 2 / Phase 3 | Recruiting | Mansoura University | 300 | 2026-06-15 | 2026-07-29 |
| Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Experimental: YB-101, Placebo YB-101 - Graves' Disease | Phase 2 | Recruiting | Yarrow Bioscience, Inc. | 232 | 2026-06-10 | 2026-10-30 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease | Phase 2 | Recruiting | Amgen | 30 | 2026-05-07 | 2026-07-23 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Anlotinib and Benmelstobart in DTC Anlotinib and Benmelstobart - Thyroid Cancer | Phase 2 | Not yet recruiting | Fudan University | 23 | 2026-04-01 | 2026-02-27 |
| Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz WP1302, WP1302 placebo, methimazole - Graves Disease | Phase 2 | Suspended | Worg Biotherapeutics Inc. | 176 | 2026-03-31 | 2025-05-08 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
Showing 20 of 314. Sign in to see all of them.
Thyroid Neoplasms (192) · Thyroid Cancer, Papillary (52) · Graves Ophthalmopathy (39) · Adenocarcinoma, Follicular (35) · Head and Neck Neoplasms (30) · Carcinoma, Non-Small-Cell Lung (29) · Neoplasms (29) · Carcinoma, Medullary (28) · Graves Disease (26) · Thyroid Carcinoma, Anaplastic (26) · Melanoma (21) · Hypothyroidism (18) · Lung Neoplasms (18) · Sarcoma (18)
Endocrine System Diseases (304) · Neoplasms by Site (207) · Endocrine Gland Neoplasms (206) · Neoplasms (194) · Head and Neck Neoplasms (182) · Neoplasms by Histologic Type (109) · Neoplasms, Glandular and Epithelial (103) · Carcinoma (95) · Adenocarcinoma (79) · Immune System Diseases (72) · Autoimmune Diseases (60) · Goiter (59) · Neoplasms, Nerve Tissue (57) · Neuroectodermal Tumors (56)
Thyroxine (16) · Magnetic Resonance Spectroscopy (13) · Triiodothyronine (12) · lenvatinib (12) · pembrolizumab (11) · trametinib (11) · Sorafenib (10) · dabrafenib (9) · Iodine-131 (8) · Thyrotropin Alfa (8) · Nivolumab (7) · Everolimus (6) · Methylprednisolone (6) · Paclitaxel (6) · Specimen Handling (5)
National Cancer Institute (NCI) (25) · M.D. Anderson Cancer Center (9) · Fudan University (8) · Memorial Sloan Kettering Cancer Center (7) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Immunovant Sciences GmbH (6) · Amgen (5) · Dana-Farber Cancer Institute (5) · Sun Yat-sen University (5) · Eli Lilly and Company (4) · Hoffmann-La Roche (4) · University of Pennsylvania (4) · Eisai Inc. (3) · Genzyme, a Sanofi Company (3) · National Cancer Center, Korea (3)
United States (173) · China (45) · France (34) · Spain (33) · Italy (32) · United Kingdom (27) · South Korea (25) · Canada (24) · Australia (21) · Germany (20) · Belgium (15) · Poland (13) · Denmark (12) · Japan (11) · Singapore (11)
Joanna Klubo-Gwiezdzinska, M.D. (4) · Dan Liang, MD (3) · Eric Sherman, MD (3) · Naris Nilubol, M.D. (3) · Alan L Ho (2) · Anne R Cappola, MD,ScM (2) · David Pfister (2) · Fangsen Xiao, MD (2) · Kartik Seghal, MD (2) · Manisha Shah (2)
PMID 37934000, PMID 40341199, PMID 27240885, PMID 27797318, PMID 31838007, PMID 33720068, PMID 37816266, PMID 40086048, PMID 10427152, PMID 12050214, PMID 16384850, PMID 16522694, PMID 16864757, PMID 17985985, PMID 18299459, PMID 18596272, PMID 18854394, PMID 19158200, PMID 19265494, PMID 19773371, PMID 20126486, PMID 20189981, PMID 20447070, PMID 20484486, PMID 20519346, PMID 20632263, PMID 20739336, PMID 20739388, PMID 20837917, PMID 20851682, PMID 21865366, PMID 22479375, PMID 22743249, PMID 22753906, PMID 22898678, PMID 22983830, PMID 23009127, PMID 23113752, PMID 23204220, PMID 23585666, PMID 23726971, PMID 23990665, PMID 24050953, PMID 24178792, PMID 24374976, PMID 24651704, PMID 24844950, PMID 25086465, PMID 25101534, PMID 25315258
2016 (5), P30CA015083 (5), 2015 (4), 2025 (4), N01CM62207 (4), 2014 (3), 2023 (3), N01CM00099 (3), N01CM62201 (3), N01CM62206 (3), 2017 (2), N01CM00071 (2), N01CM62202 (2), N01CM62203 (2), N01CM62205 (2)